Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
National Cancer Institute (NCI)
AstraZeneca
All India Institute of Medical Sciences, Bhubaneswar
Stanford University
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
The Methodist Hospital Research Institute
PMV Pharmaceuticals, Inc
Mayo Clinic
Tomsk National Research Medical Center of the Russian Academy of Sciences
National Institutes of Health Clinical Center (CC)
Merck Sharp & Dohme LLC
Kivu Bioscience Inc.
Ambrx, Inc.
Alterome Therapeutics, Inc.
Eli Lilly and Company
Eli Lilly and Company
Baptist Health South Florida
Dana-Farber Cancer Institute
ViroMissile, Inc.
Eli Lilly and Company
AstraZeneca
West German Study Group
Institut Curie
IntoCell, Inc
Tizona Therapeutics, Inc
Essen Biotech
Essen Biotech
AstraZeneca
Clasp Therapeutics, Inc.
Icahn School of Medicine at Mount Sinai
Eli Lilly and Company
Angiex, Inc.
NiKang Therapeutics, Inc.
Celcuity Inc
Ottawa Hospital Research Institute
MacroGenics
Nanjing Sanhome Pharmaceutical, Co., Ltd.
AstraZeneca
Centre Paul Strauss
Wake Forest University Health Sciences
ALX Oncology Inc.
General Oncology, Inc.
Vanderbilt-Ingram Cancer Center
University of Maryland, Baltimore
DualityBio Inc.